Clinical trials: Obstructive Pulmonary Diseases
Chronic Bronchitis, Copd Bronchitis
Gala Early Feasibility Study of RheOx
An early feasibility study (EFS) to assess the safety and clinical utility of RheOx on patients with chronic bronchitis in the United States.
- Trial name
- Gala_EFS (NCT03631472)
- Testing
- RheOx
- Where
- 8 sites in United States
- Volunteers
- 21 people
- Sponsor
- Gala Therapeutics, Inc.
Asthma
Role of the Isomerase Pin-1 in the Development and Treatment of Asthma
Pin1 is activated in asthmatic airways, increasing cytokine mRNA stability and eosinophil survival. This study is designed to test whether the Pin1 enzyme regulates TLR/IL-1R signal pathways in multiple cells in asthma.
- Trial name
- Pin1 (NCT01691612)
- Testing
- installation of D. pteronyssinus allergens
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Brigham and Women's Hospital
COPD
Peak Inspiratory Flow and Dry Powder Inhaler Performance in COPD
The purpose of the study is to determine whether PIF is clinically important when using the Ellipta DPI device. In addition, the study will validate the best/most clinically appropriate way to perform a PIF maneuver, to determine…
- Trial name
- NCT04606394
- Testing
- Trelegy Ellipta 100/62.5/25Mcg Inh 30D, Ventolin 90Mcg/Actuation Inhalation Aerosol
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Pulmonary Research Institute of Southeast Michigan
Asthma
Effect of Montelukast on Experimentally-Induced RV16 Infection in Asthma
People with asthma may have asthma worsening when they have an upper respiratory infection due to a virus or a common cold. Leukotrienes are increased in nasal secretions from children with Respiratory Syncytial Virus (RSV) and…
- Trial name
- NCT00359073
- Testing
- montelukast
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University of Wisconsin, Madison
Asthma
A Trial of Mepolizumab Adjunctive Therapy for the Prevention of Asthma Exacerbations in Urban Children
The purpose of this study is to see if treatment with a medication called Nucala® (mepolizumab), given along with standard asthma care, makes children less likely to have asthma attacks.
- Trial name
- MUPPITS-2 (NCT03292588)
- Testing
- Mepolizumab
- Where
- 9 sites in United States
- Volunteers
- 335 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Pulmonary Disease, Chronic Obstructive
Bone Mineral Density Study In Patients With Chronic Obstructive Pulmonary Disease. DISKUS® Inhaler is a Trademark of the GSK Group of Companies.
This study will last up to 3 years. You will visit the clinic up to 14 times. Certain visits will include lung function tests and scans of your bones.
- Trial name
- NCT00355342
- Testing
- Salmeterol 50 mcg BID, Fluticasone Propionate/Salmeterol 250/50 mcg BID, DISKUS inhaler
- Where
- 37 sites in United States
- Volunteers
- 186 people
- Sponsor
- GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive
The Impact of a Home-based Pulmonary Telerehabilitation Program in Acute Exacerbations of COPD
COPD impacts a significant proportion of the Veteran population. Acute exacerbations, or flare-ups, of COPD are associated with impaired muscle function and worse quality of life.
- Trial name
- NCT03997513
- Testing
- Pulmonary Telerehabilitation
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- VA Office of Research and Development
Chronic Obstructive Pulmonary Disease (COPD)
A Trial Assessing LAS34273 in Moderate to Severe Stable Chronic Obstructive Pulmonary Disease (COPD)
To evaluate the efficacy and safety of LAS 34273 compared to placebo in patients with moderate to severe COPD during one year of treatment.
- Trial name
- NCT00363896
- Testing
- Aclidinium bromide
- Where
- 132 sites in Andorra, Austria and 14 more
- Volunteers
- 843 people
- Sponsor
- AstraZeneca
Pharmacokinetics, Epinephrine
Study of Drug Exposure in Systemic Circulation of Primatene Mist by Oral Inhalation, Versus Epinephrine Injection by Intramuscular Injection and ProAir by Oral Inhalation in Healthy Individuals
To assess the drug exposure profile in systemic circulation of Primatene Mist by inhalation, versus Epinephrine by intramuscular injection, and ProAir HFA by inhalation in healthy adults.
- Conditions
- Pharmacokinetics, Epinephrine, Albuterol, Asthma
- Trial name
- NCT04207840
- Testing
- Epinephrine (0.125 mg/inhalation), Epinephrine Injection Auto-Injector (0.3mg/0.3mL), Albuterol Sulfate (0.09 mg/inhalation)
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Amphastar Pharmaceuticals, Inc.
Pulmonary Disease, Chronic Obstructive
A Long-term Safety Study of Fluticasone Furoate (FF)/GW642444 in Japanese Subjects With COPD
The primary purpose of the study is to evaluate the safety and tolerability of fluticasone furoate/GW642444 inhalation powder when administered once-daily for 52 weeks in Japanese patients with COPD.
- Trial name
- NCT01192191
- Testing
- Fluticasone Furoate/GW642444 Inhalation Powder 100/25mcg, Fluticasone Furoate/GW642444 Inhalation Powder 200/25mcg
- Where
- 35 sites in Japan
- Volunteers
- 187 people
- Sponsor
- GlaxoSmithKline
Asthma
A Dose Ranging Study With CHF 1531 in Subjects With Asthma (FLASH)
To evaluate the dose-response of different doses of CHF 1531 pressurized metered dose inhaler (pMDI) containing formoterol fumarate, on lung function and other clinical outcomes and to identify the optimal dose(s) with regard to…
- Trial name
- FLASH (NCT03086460)
- Testing
- CHF 1531 pMDI, Formoterol Inhalation Solution
- Where
- 10 sites in United States
- Volunteers
- 67 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Asthma
A Single Dose PD & PK Study With Two Formulations of Abediterol in Patients With Asthma
The purpose of this study is to investigate the pharmacodynamics of single doses of abediterol given by 2 different devices in participants with asthma.
- Trial name
- NCT02777827
- Testing
- Abediterol 0.156 μg, Abediterol 2.5 μg, Abediterol 0.05 μg
- Where
- 4 sites in Germany
- Volunteers
- 30 people
- Sponsor
- AstraZeneca
Pulmonary Disease, Chronic Obstructive
Cross-Over Study in Subjects With COPD, Evaluating Lung Function Response After Treatment With Once Daily Umeclidinium 62.5mcg, Vilanterol 25mcg, and Umeclidinium/Vilanterol 62.5/25mcg
The purpose of this study is to evaluate the lung function response to UMEC/VI, UMEC, and VI in individual patients using a cross-over design. This is a multicenter, randomized, double-blind, 3-way crossover study.
- Trial name
- NCT01716520
- Testing
- Umeclidinium/Vilanterol 62.5/25 mcg, Umeclidinium 62.5 mcg, Vilanterol 25 mcg
- Where
- 21 sites in Estonia, Germany
- Volunteers
- 182 people
- Sponsor
- GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive
A Cross-Over Study to Evaluate Lung Function Response After Treatment With Umeclidinium (UMEC) 62.5 Micrograms (mcg), Vilanterol (VI) 25 mcg, and Umeclidinium/Vilanterol (UMEC/VI) 62.5/25 mcg Once-Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
This is a multicenter, randomized, double-blind, 3-way crossover study to evaluate the lung function response to UMEC 62.5 mcg, VI 25 mcg, and UMEC/VI 62.525 mcg, administered once-daily via a novel dry powder inhaler (NDPI) over…
- Trial name
- NCT02014480
- Testing
- Umeclidinium 62.5 mcg, Vilanterol 25 mcg, Umeclidinium/Vilanterol 62.5/25 mcg
- Where
- 21 sites in Slovakia, Ukraine
- Volunteers
- 207 people
- Sponsor
- GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive
A Dose Ascending, Study To Examine The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of GSK233705B.
GSK233705 is a high-affinity specific muscarinic receptor (mAChR) antagonist which is being developed for the treatment of chronic obstructive pulmonary disease.
- Trial name
- NCT00453479
- Testing
- GSK233705B
- Where
- 4 sites in Netherlands
- Volunteers
- 23 people
- Sponsor
- GlaxoSmithKline
Chronic Obstructive Pulmonary Disease
A Proof-of-mechanism Study of Multiple, Oral Doses of Fevipiprant (QAW039) in COPD Patients With Eosinophilia
This was an exploratory, randomized, subject- and investigator-blind, placebo-controlled, parallel group, proof-of-mechanism study of multiple oral doses of fevipiprant (QAW039) in chronic obstructive pulmonary disease (COPD)…
- Trial name
- NCT03810183
- Testing
- QAW039
- Where
- 4 sites in Germany, United Kingdom
- Volunteers
- 9 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Obstructive Pulmonary Disease (COPD)
Evaluation of the Efficacy and Safety of MV130 in Chronic Obstructive Pulmonary Disease (COPD)
The goal of this clinical trial is to learn whether the bacterial vaccine MV130 helps reduce the number of exacerbations in adults with moderate to severe COPD. It will also assess the safety and immune effects of MV130.
- Trial name
- MV130 (NCT01842360)
- Testing
- MV130
- Where
- 7 sites in Spain
- Volunteers
- 198 people
- Sponsor
- Inmunotek S.L.
Asthma
A 24-Week Treatment Study to Compare Standard of Care Versus the eMDPI DS in Participants 13 Years or Older With Asthma
The primary objective of this study is to demonstrate the effectiveness of the Digital System (DS) in improving asthma control compared to the Standard of Care (SoC) group.
- Trial name
- CONNECT2 (NCT04677959)
- Testing
- Fluticasone propionate/salmeterol (FS), Albuterol, Standard of Care Asthma Medication
- Where
- 46 sites in United States
- Volunteers
- 427 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Chronic Obstructive Pulmonary Disease Moderate
The Effects of RPL554 in Addition to Tiotropium in COPD Patients
This is a phase II, randomised, double blind, placebo controlled, complete block, three way crossover study to investigate treatment with nebulised RPL554 and tiotropium together in patients with moderate to severe chronic…
- Trial name
- NCT03028142
- Testing
- 1.5 mg RPL554 plus tiotropium, 6 mg RPL554 plus tiotropium
- Volunteers
- 30 people
- Sponsor
- Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA
Pulmonary Disease, Chronic Obstructive
Co-administration of Olodaterol Respimat® and Tiotropium Handihaler®
The overall objective of this study is to assess efficacy and safety of 12 weeks, once daily, orally inhaled co-administration of olodaterol 5 µg (delivered by the Respimat® Inhaler) and tiotropium (delivered by the Handihaler®…
- Trial name
- NCT01694771
- Testing
- Tiotropium, Olodaterol
- Where
- 90 sites in United States
- Volunteers
- 1,134 people
- Sponsor
- Boehringer Ingelheim
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.